Trial Profile

Real-world Evaluation of Efficacy and Safety With Avelumab (BAVENCIO) + Axitinib (INLYTA) in Patients With aRCC in Multiple EU Countries (AVION)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 15 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Axitinib (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms AVION
Sponsors Merck KGaA

Most Recent Events

11 Jun 2024 Planned primary completion date changed from 9 May 2024 to 8 Aug 2024.
17 May 2023 Planned End Date changed from 9 Sep 2025 to 9 May 2025.
17 May 2023 Planned primary completion date changed from 9 Sep 2024 to 9 May 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com